Alpiropride

Alpiropride
Clinical data
Trade namesRevistel, Rivistel, or Rivestel
Other namesIristel; RIV-2093; RIV2093; RIV 2093; Riv 2093; Riv-2093; Riv2093
Drug classDopamine D2 receptor antagonist; Antihypertensive agent; Antimigraine agent
Identifiers
  • 4-amino-2-methoxy-5-(methylsulfamoyl)-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]benzamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.072.585 Edit this at Wikidata
Chemical and physical data
FormulaC17H26N4O4S
Molar mass382.48 g·mol−1
3D model (JSmol)
  • CNS(=O)(=O)C1=C(C=C(C(=C1)C(=O)NCC2CCCN2CC=C)OC)N
  • InChI=1S/C17H26N4O4S/c1-4-7-21-8-5-6-12(21)11-20-17(22)13-9-16(26(23,24)19-2)14(18)10-15(13)25-3/h4,9-10,12,19H,1,5-8,11,18H2,2-3H3,(H,20,22)
  • Key:QRQMZZNDJGHPHZ-UHFFFAOYSA-N

Alpiropride (INNTooltip International Nonproprietary Name; brand name Revistel, Rivistel, or Rivestel) is a dopamine D2 receptor antagonist of the benzamide group related to sulpiride.[1][2][3][4][5] It is described as an antihypertensive agent and has been marketed for use as an antimigraine medication in Portugal.[1][4][2] The drug was first described by 1980[1] and was introduced for medical use by 1989.[4] It remained marketed in Portugal as late as 2000.[2]

  1. ^ a b c Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 33. ISBN 978-1-4757-2085-3. Retrieved 24 October 2024.
  2. ^ a b c Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 31. ISBN 978-3-88763-075-1. Retrieved 24 October 2024.
  3. ^ Milne GW (2018). Drugs: Synonyms and Properties. Routledge Revivals. Taylor & Francis. p. 358. ISBN 978-1-351-78990-5. Retrieved 24 October 2024.
  4. ^ a b c Ong HH, Allen RC (1989). "Chapter 31. To Market, To Market -1988". Annual Reports in Medicinal Chemistry. Vol. 24. Elsevier. pp. 295–315. doi:10.1016/s0065-7743(08)60553-9. ISBN 978-0-12-040524-4. ISSN 0065-7743.
  5. ^ Ren S, Lien LL, Lien EJ (August 1997). "Molecular modeling and structural analysis of benzamide derivatives with and without extrapyramidal syndrome side effects.". Current Medicinal Chemistry. Vol. 4. Bentham Science Publishers. pp. 271-278 (275). Retrieved 24 October 2024.